Sanofi and Upsa rule out the risk of shortages, but increase the production rate.
For the past week, purchases of Doliprane, Dafalgan and Efferalgan have been rationed. The Medicines Agency (ANSM) recommends that pharmacies favor the dispensing of these paracetamol-based medicines by prescription and limit them to two boxes for patients without a prescription.
This decision is explained by delays in the supply of paracetamol in sachets, syrups, tablets, capsules and suppositories observed in certain pharmacies since January. These follow production difficulties to which is added an increase in consumption in the context in particular of the seventh wave of Covid-19”, details the ANSM, which provides for a return to normal after the summer.
Avoid the pharmacy rush
Following this notice, the two main manufacturers, Sanofi (Doliprane) and Upsa (Efferalgan, Dafalgan) wanted to reassure in order to avoid the rush in pharmacies, as was the case during the first wave of Covid. There is no risk of rupture of paracetamol Sanofi…
This article is for subscribers only. You have 70% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
Already subscribed? Login